Among the well-known biomarkers, such as PDL1 and the PD1–PDL1 axis, TMB (tumor mutational burden), and others, the microbiota potentially appears to be the most relevant predictor of immunotherapeutic efficacy. This evidence concerns the gene CD274 and neoplasm.